...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Integrative cancer therapies >Lung cancer survival with herbal medicine and vitamins in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods.
【24h】

Lung cancer survival with herbal medicine and vitamins in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods.

机译：草药和维生素在整个系统中的肺癌生存率：使用边缘结构模型和倾向评分方法分析的十年随访数据。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Complementary and alternative medicines are used by up to 48% of lung cancer patients but have seen little formal assessment of survival efficacy. In this 10-year retrospective survival study, the authors investigated Pan-Asian medicine + vitamins (PAM+V) therapy in a consecutive case series of all non-small-cell lung cancer patients (n = 239) presenting at a San Francisco Bay Area Chinese medicine center (Pine Street Clinic). They compared short-term treatment lasting the duration of chemotherapy/radiotherapy with long-term therapy continuing beyond conventional therapy. They also compared PAM+V plus conventional therapy with conventional therapy alone, using concurrent controls from the Kaiser Permanente Northern California and California Cancer Registries. They adjusted for confounding with Kaplan-Meier, Cox regression, and newer methods - propensity score and marginal structural models (MSMs), which when analyzing data from observational studies or clinical practice records can provide results comparable with randomized trials. Long-term use of PAM+V beyond completion of chemotherapy reduced stage IIIB deaths by 83% and stage IV by 72% compared with short-term use only for the duration of chemotherapy. Long-term PAM+V combined with conventional therapy reduced stage IIIA deaths by 46%, stage IIIB by 62%, and stage IV by 69% compared with conventional therapy alone. Survival rates for stage IV patients treated with PAM+V were 82% at 1 year, 68% at 2 years, and 14% at 5 years. PAM+V combined with conventional therapy improved survival in stages IIIA, IIIB, and IV, compared with conventional therapy alone. Prospective trials using PAM+V with conventional therapy for lung cancer patients are justified.
机译：多达48％的肺癌患者使用辅助和替代药物，但几乎没有正式评估其生存功效。在这项为期10年的回顾性生存研究中，作者对旧金山湾出现的所有非小细胞肺癌患者（n = 239）的连续病例系列中的泛亚医学+维生素（PAM + V）治疗进行了研究。地区中医中心（松街诊所）。他们将持续化疗/放疗的短期治疗与持续治疗超出常规治疗的长期治疗进行了比较。他们还使用来自北加州凯撒永久医院和加利福尼亚癌症登记处的并发对照，将PAM + V加常规疗法与单独常规疗法进行了比较。他们调整了与Kaplan-Meier，Cox回归和较新方法-倾向得分和边缘结构模型（MSM）的混淆，当分析观察性研究或临床实践记录的数据时，可以提供与随机试验相当的结果。与仅在化疗期间短期使用相比，在化疗结束后长期使用PAM + V可使IIIB期死亡减少83％，IV期减少72％。与单独的常规疗法相比，长期PAM + V联合常规疗法可使IIIA期死亡率降低46％，IIIB期死亡率降低62％，IV期降低69％。使用PAM + V治疗的IV期患者的生存率在1年时为82％，在2年时为68％，在5年时为14％。与单独的常规治疗相比，PAM + V联合常规治疗可改善IIIA，IIIB和IV期的生存率。使用PAM + V联合常规疗法治疗肺癌患者的前瞻性试验是合理的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号